Complications of Renal Transplantation

  • Peter J. Morris


Although complications following renal transplantation are now fewer than in the earlier years of transplantation, they are nevertheless still responsible for appreciable morbidity and even mortality in the transplant recipient. Such complications are diverse in nature, ranging from technical problems related to the surgery to more widespread effects related to immunosuppression and/or poor renal function.


Transplant Recipient Renal Transplantation Renal Transplant Recipient Renal Artery Stenosis Renal Vein Thrombosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D’Apuzzo V, Bretscher D, Oetliker O, Nachbur B: Renal vein thrombosis in kidney allografts. Lancet 2: 975–976, 1973.PubMedCrossRefGoogle Scholar
  2. 2.
    Sorensen BL, Hald T, Nissen HM: Silent iliac compression syndrome as a cause of renal vein thrombosis after transplantation. Scand J Urol Nephrol 6 (Suppl 15): 75–77, 1972.PubMedCrossRefGoogle Scholar
  3. 3.
    Merion RM, Caine RY: Allograft renal vein thrombosis. Transplant Proc 17: 1746–1750, 1985.PubMedGoogle Scholar
  4. 4.
    Jones RM, Murie JA, Ting A, Dunnill MS, Morris PJ: Renal vascular thrombosis of cadaveric renal allografts in patients receiving cyclosporin, azathioprine and prednisolone triple therapy. Clin Transplant 2: 122–126, 1988.Google Scholar
  5. 5.
    Akyol AM, Briggs JD, Junor BJR, et al.: Renal vein thrombosis after cadaveric renal transplantation. Presented to the Association of Surgeons of Great Britain and Ireland, Oxford, 1991.Google Scholar
  6. 6.
    Gruber SA, Chavers B, Payne WD, et al.: Allograft renal vascular thrombosis: lack of increase with cyclosporine immunosuppression. Transplantation 47: 475–478, 1989.PubMedCrossRefGoogle Scholar
  7. 7.
    McKenzie N, Deviveni R, Vezina W, Keown P, Stiller C: The effect of cyclosporin on organ blood flow. Transplant Proc 17: 1973–1975, 1985.PubMedGoogle Scholar
  8. 8.
    Petric R, Freeman D, Wallace C, McDonald J, Stiller C, Keown P: Effect of cyclosporine on urinary prostanoid excretion, renal blood flow and glomerulotubular function. Transplantation 45: 883–889, 1988.PubMedCrossRefGoogle Scholar
  9. 9.
    Brown Z, Neild GH: Cyclosporine inhibits prostacyclin production by cultured human endothelial cells. Transplant Proc 19: 1178–1180, 1987.PubMedGoogle Scholar
  10. 10.
    Neild GH, Rocchi G, Imberti L, et al.: Effect of cyclosporin A on prostacyclin synthesis by vascular tissue. Thromb Res 32: 373–379, 1983.PubMedCrossRefGoogle Scholar
  11. 11.
    Vanrenterghem Y, Roels L, Lerut T, et al.: Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1: 999–1002, 1985.PubMedCrossRefGoogle Scholar
  12. 12.
    Baker LR, Tucker B, Kovacs IB: Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients. Transplantation 49: 905–909, 1990.PubMedCrossRefGoogle Scholar
  13. 13.
    Bergentz SE, Bergqvisst D, Bornmyr S, Brunkwall J, Husberg B: Venous thrombosis and cyclosporin. Lancet 2: 101–102, 1985.CrossRefGoogle Scholar
  14. 14.
    Richardson AJ, Higgins RM, Jaskowski AJ, et al.: Spontaneous rupture of renal allografts: the importance of renal vein thrombosis in the cyclosporin era. Br J Surg 77: 558–560, 1990.PubMedCrossRefGoogle Scholar
  15. 15.
    Roberts JP, Ascher NL, Fry DS, et al.: Transplant renal artery stenosis. Transplantation 48: 580–583, 1989.PubMedGoogle Scholar
  16. 16.
    Benoit G, Hiesse C, Icard P, et al.: Treatment of renal artery stenosis after renal transplantation. Transplant Proc 19: 36003601, 1987.Google Scholar
  17. 17.
    Greenstein SM, Verstandig A, McLean GK, et al.: Percutaneous transluminal angioplasty, the procedure of choice in the hypertensive renal allograft recipient with renal artery stenosis. Transplantation 43: 29–32, 1987.PubMedCrossRefGoogle Scholar
  18. 18.
    Morris Pi, Yadav R, Kincaid-Smith P, Anderson J, Hare WSC, Johnson N, Johnson W, Marshall VC: Renal artery stenosis in renal transplantation. Med J Aust 1: 1255–1257, 1971.PubMedGoogle Scholar
  19. 19.
    Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP: Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med 308: 377–381, 1983.PubMedCrossRefGoogle Scholar
  20. 20.
    Tilney NL, Rocha A, Strom TB, Kirkman RL: Renal artery stenosis in transplant patients. Ann Surg 199: 454–460, 1984.PubMedCrossRefGoogle Scholar
  21. 21.
    Hricik DE: Antihypertensive and renal effects of enalapril in post-transplant hypertension. Clin Nephrol 27: 250–259, 1987.PubMedGoogle Scholar
  22. 22.
    Gray DW: Vascular and lymphatic complications after renal transplantation. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 4th ed. WB Saunders, Philadelphia, pp 314–329, 1994.Google Scholar
  23. 23.
    Morris PJ: Renovascular hypertension: the indications for and results of surgery. In: P Bell, C Jamieson, CV Ruckley, eds, Surgical Management of Vascular Disease. WB Saunders, philadelphia, pp 739–750, 1992.Google Scholar
  24. 24.
    Mundy AR, Podesta ML, Bewick M, Rudje CJ, Ellis FG: The urological complications of 1000 renal transplants. Br J Urol 53: 397–402, 1981.PubMedCrossRefGoogle Scholar
  25. 25.
    Loughlin KR, Tilney NL, Richie JP: Urological complications in 718 renal transplant patients. Surgery 95: 297–302, 1984.PubMedGoogle Scholar
  26. 26.
    Cranston D: Urological complications after renal transplantation. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 4th ed. WB Saunders, Philadelphia, pp 330–338, 1994.Google Scholar
  27. 27.
    Petrek J, Tilney NL, Smith EH, Williams JS, Vineyard GC: Ultrasound in renal transplantation. Ann Surg 185: 441–447, 1975.CrossRefGoogle Scholar
  28. 28.
    Jaskowski A, Jones RM, Murie JA, Morris PJ: Urological complications in 600 consecutive renal transplants. Br J Surg 74: 922–925, 1987.PubMedCrossRefGoogle Scholar
  29. 29.
    Griffiths AB, Fletcher EW, Morris PJ: Lymphocele after renal transplantation. Aust NZ J Surg 49: 626–628, 1979.CrossRefGoogle Scholar
  30. 30.
    Cohen J, Hopkin J, Kurtz J: Infectious complications after renal transsplantation. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 4th ed. WB Saunders, Philadelphia, pp 364–389, 1994.Google Scholar
  31. 31.
    Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE: Infections in the renal transplant recipient. Am J Med 70; 405–411, 1981.PubMedCrossRefGoogle Scholar
  32. 32.
    Tobin JO’H, Beare J, Dunnill MS, Fisher-Hoch S, French M, Mitchell RG, Morris PJ, Meurs MF: Legionnaire’s disease in a transplant unit: isolation of the causative agent from shower baths. Lancet 2: 118–121, 1980.PubMedCrossRefGoogle Scholar
  33. 33.
    Rubin RH: The problem of cytomegalovirus infection in transplantation. In: PJ, Morris, NL Tilney, eds, Progress in Transplantation II. Churchill Livingstone, Edinburgh, pp 89–114, 1984.Google Scholar
  34. 34.
    Warrell MJ, Chinn I, Morris PJ, Tobin JO: The effects of viral infection on renal transplants and their recipients. Q J Med 49: 219–231, 1980.PubMedGoogle Scholar
  35. 35.
    Richardson WP, Colvin RB, Cheeseman H, Tolkoff-Rubin NE, Herrin JT, Cosimi AB, Collins AB, Hirsch MS, McCluskey RT, Russell PS, Rubin RH: Glomerulopathy associated with cytomegalovirus uremia in renal allografts. N Engl J Med 305: 57–63, 1981.PubMedCrossRefGoogle Scholar
  36. 36.
    Einsele H, Steidle M, Vallbracht A, et al.: Early occurrence of CMV infection after BMT as demonstrated by PCR technique. Blood 77: 1104–1110, 1991.PubMedGoogle Scholar
  37. 37.
    van der Bij W, Schirm J, Torensma R, et al.: Comparison of viremia and antienemia for detection of cytomegalovirus in blood. J Clin Microbiol 26: 2531–2535, 1988.PubMedGoogle Scholar
  38. 38.
    van der Bij W, Torensma R, van Son WJ, et al.: Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 25: 179–188, 1988.PubMedCrossRefGoogle Scholar
  39. 39.
    Collaborative DHPG Treatment Study Group: Treatment of serious cytomegalovirus infections with 9-(1.3-dihydroxy2-propoxymethyl) guanine in patients with AIDS and other immunodeficiences. N Engl J Med 314: 801–805, 1986.CrossRefGoogle Scholar
  40. 40.
    Reed EC, Bowden RA, Dandliker PS, et al.: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109: 783–788, 1988.PubMedCrossRefGoogle Scholar
  41. 41.
    Deray G, Martinez F, Katlama C, et al.: Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 9: 316–321, 1989.PubMedCrossRefGoogle Scholar
  42. 42.
    Plotkin SA, Starr SE, Friedman HM, et al.: Effect of Town live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 114: 525–531, 1991.PubMedCrossRefGoogle Scholar
  43. 43.
    Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA, Shope TC, Spector SA: Dankner WM Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58: 1176–1178, 1994.PubMedGoogle Scholar
  44. 44.
    Snydman DR, Werner GB, Tilney NC, et al.: Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transplant Proc 23: 1357–1360, 1991.PubMedGoogle Scholar
  45. 45.
    Balfour HH, Chace BA, Stapleton MD, et al.: A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320: 1381–1387, 1989.PubMedCrossRefGoogle Scholar
  46. 46.
    Merigan TC, Renlund DG, Keay S, et al.: A controlled trial of gangiclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 326: 1182–1186, 1992.PubMedCrossRefGoogle Scholar
  47. 47.
    Pirison Y, Alexandre GP, van Ypersele de Strihou C: Longterm effects of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 296: 194–196, 1977.CrossRefGoogle Scholar
  48. 48.
    Parfrey PS, Forbes RDC, Hutchinson TA, Beaudoin JG,Dauphine WD, Hollomby DJ, Guttmann RD: The clinical and pathological cause of hepatitis B liver disease in renal transplant recipients. Transplantation 37: 461–466, 1984.PubMedCrossRefGoogle Scholar
  49. 49.
    La Quaglia MP, Tolkoff-Rubin NE, Dienstag JL, Cosimi AB, Herrin JT, Kelly M, Rubbin RH: Impact of hepatitis on renal transplantation. Transplantation 32: 504–507, 1981.CrossRefGoogle Scholar
  50. 50.
    Fairley CK, Mijch A, Gust ID, et al.: The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBY DNA positive. Transplantation 52: 497–500, 1991.PubMedCrossRefGoogle Scholar
  51. 51.
    Alter HI, Purcell RH, Shih JW, et al.: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321: 1494–1500, 1989.PubMedCrossRefGoogle Scholar
  52. 52.
    Pereira BJG, Milford EL, Kirkman RL, Levey AS: Transmission of hepatitis C by organ transplantation. N Engl J Med 325: 454–460, 1991.PubMedCrossRefGoogle Scholar
  53. 53.
    Davis GI, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C with r recombinant interferon alpha. A multi center randomized, controlled trial. N Engl J Med 321: 1501–1506, 1989.PubMedCrossRefGoogle Scholar
  54. 54.
    L’Age-Stehr J, Schwarz A, Offermann G, et al.: HTLV-III in renal transplant recipients. Lancet 2: 1361–1362, 1985.PubMedCrossRefGoogle Scholar
  55. Lang P, Niaudert P, and the Groupe Cooperatif de Transplantation d’Ile de France. HIV infection in renal transplant patients. In: JL Touraine et al. eds, Transplantation and Clinical Immunology,vol 23. Excerpta Medica, Amsterdam, pp 221, 1991.Google Scholar
  56. 56.
    Ritchie DB, Jennings LC, Lynn KL, Bailey RR, Cook HB: Clostridium difficile-associated colitis: cross-infection in predisposed patients with renal failure. NZ Med J 95: 265–266, 1982.Google Scholar
  57. 57.
    Raine AEG: Cardiovascular complications after renal transplantation. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 4th ed. WB Saunders, Philadelphia, pp 339–355, 1994.Google Scholar
  58. 58.
    Raine AEG: Cardiovascular complications after renal transplantation. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 3rd ed. WB Saunders, Philadelphia, pp 575–601, 1988.Google Scholar
  59. 59.
    Kirkman RL, Strom TB, Weir MR, Tilney NL: Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 34: 347–351, 1982.PubMedCrossRefGoogle Scholar
  60. 60.
    Bennett WM, McDonald WJ, Lawson RK, Potter GA: Post-transplant hypertension: Studies of cortical blood flow and the renal pressor system. Kidney Int 6: 99–108, 1974.PubMedCrossRefGoogle Scholar
  61. 61.
    Dustan HP: Inhibition of angiotensin converting enzyme in renal transplant recipients with hypertension. N Engl J Med 308: 377–381, 1983.PubMedCrossRefGoogle Scholar
  62. 62.
    Linas SL, Miller PD, McDonald KM, Stables DP, Katz F, Weil R, Schrier RW: Role of the renin-angiotensin system in post-transplantation hypertension in patients with multiple kidneys. N Engl J Med 298: 1440–1444, 1978.PubMedCrossRefGoogle Scholar
  63. 63.
    Curtis JJ, Luke RG, Diethelm AG, Whelchel JD, Jones P: Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 2: 729–745, 1985.Google Scholar
  64. 64.
    Taylor HM, Benjamin IS, Morris PJ: Control of hypertension after renal transplantation by embolisation of host kidneys. Lancet 2: 424–427, 1984.PubMedGoogle Scholar
  65. 65.
    Bennett WM, Porter GA: Cyclosporine-associated hypertension. Am J Med 85: 131–133, 1988.PubMedCrossRefGoogle Scholar
  66. 66.
    Schachter M: Cyclosporine A and hypertension. J Hypertens 6: 511–516, 1988.PubMedCrossRefGoogle Scholar
  67. 67.
    Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 84: 985–992, 1988.PubMedCrossRefGoogle Scholar
  68. 68.
    Vathsala, A, Weinberg RB, Schoenberg L, et al.: Lipid abnormalities in cyclosporine-prednisolone-treated renal transplant recipients. Transplantation 48: 37–43, 1989.PubMedCrossRefGoogle Scholar
  69. 69.
    Webb AT, Plant M, Reaveley DA, et al.: Lipid and lipoprotein (a) concentrations in renal transplant patients. Nephrol Dial Transplant 7: 636–641, 1992.PubMedGoogle Scholar
  70. 70.
    Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319: 24–33, 1988.PubMedCrossRefGoogle Scholar
  71. 71.
    Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al.: Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 49: 95–100, 1990.PubMedCrossRefGoogle Scholar
  72. 72.
    Allen RD, Michie CA, Murie JA, Morris PJ: Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 164: 137–142, 1987.PubMedGoogle Scholar
  73. 73.
    Vanrenterghem Y, Roels L, Lerut T, Gruwez J, Michielsen P, Gresele P, Deckmyn H, Colucci M, Arnout J, Vermylen J: Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1: 999–1002, 1985.PubMedCrossRefGoogle Scholar
  74. 74.
    Allen RD, Michie CA, Morris PJ, Chapman JR: Venous thrombosis and cyclosporin. Lancet 2: 1004, 1985.PubMedCrossRefGoogle Scholar
  75. 75.
    Sheil AGR: Cancer in dialysis and transplant patients. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 4th ed. WB Saunders, Philadelphia, pp 390–400, 1994.Google Scholar
  76. 76.
    Penn I: The changing pattern of post-transplant malignancies. Transplant proc 23: 1101–1103, 1991.PubMedGoogle Scholar
  77. 77.
    Yenning VA: Non-malignant skin lesions in renal transplant patients. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 4th ed. WB Saunders, Philadelphia, pp 401–411, 1994.Google Scholar
  78. 78.
    Hanto DW, Simmons RL: Lymphoproliferative disease in immunosuppressed patients. In: PJ Morris, NL Tilney, eds, Progress in Transplantation, vol 1. Churchill Livingstone, New York, pp 186–208, 1994.Google Scholar
  79. 79.
    Walker RG, D’Apice AJ: Non-specific immunosuppression: azathioprine and steroids. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 4th ed. WB Saunders, Philadelphia, pp 202–214, 1994.Google Scholar
  80. 80.
    Fine R, Ettenger R: Renal transplantation in children. In: PJ Morris, ed, Kidney Transplantation: Principles and Practice, 4th ed. WB Saunders, Philadelphia, pp 412–459, 1994.Google Scholar
  81. 81.
    Klare B, Walter JV, Hahn H, Emmrich P, Land W: Cyclosporin in renal transplantation in children. Lancet 2: 692, 1984.PubMedCrossRefGoogle Scholar
  82. 82.
    Fletcher SM, Conley SB, van Buren CT, Rose G, Kerman R, Kahan BD: Impact of cyclosporin on renal function and growth in pediatric renal transplant recipients. Transplant Proc 17: 1284–1288, 1985.Google Scholar
  83. 83.
    Shun-Shin GA, Ratcliffe P, Brou AJ, Brown NP, Sparrow JM: The lens after renal transplantation. Br J Opthalmol 74: 26 1271, 1990.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Peter J. Morris
    • 1
  1. 1.Nuffield Department of SurgeryUniversity of Oxford, Oxford Radcliffe Hospital The John RadcliffeHeadington, OxfordUK

Personalised recommendations